Modelling the whole pipeline: A new platform targets manufacturing of vaccines and other biopharmaceuticals

May 2026

Inno4Vac researchers have developed CADET-Hub, a modular, cloud-based platform that brings together the full biomanufacturing modelling workflow in a single, browser-accessible environment. The work, published in Computers & Chemical Engineering, was carried out within the Inno4Vac project (subtopic 4).

CADET-Hub integrates upstream and downstream bioprocess modelling with stability forecasting. The upstream modules are based on efficient compartment models derived from computational fluid dynamics and metabolic models for bioreactor simulation. The downstream processing unit operations include centrifugation, filtration, and chromatography. A dedicated stability module rounds off the platform, enabling shelf-life prediction of biological products through Bayesian and kinetic modelling approaches.

“With this collaborative project we managed to combine the different building blocks of biomanufacturing processes into a single integrated platform, aiming to accelerate process development and optimization, whilst reducing experimental workload and costs”

-states Dr Reinhard Liebers, author and Project Manager at the European Vaccine Initiative (EVI).

A significant part of the development was regulatory alignment. The team engaged with regulatory bodies throughout the project to ensure that model development, validation, and documentation practices meet expectations for biopharmaceutical applications. The platform further supports FAIR-compliant and collaborative workflows, requiring no local software installation.

The developers expect CADET-Hub to help reduce reliance on costly wet lab experiments and accelerate process development, scale-up, and scale-down in vaccine and biopharmaceuticals manufacturing through predictive modelling.

Full article: https://doi.org/10.1016/j.compchemeng.2026.109690

This work has received support from the Innovative Medicines Initiative/European Union/European Federation of Pharmaceutical Industries and Associations (IMI2/EU/EFPIA) Joint Undertaking under grant agreement no. 101007799 (Inno4Vac). This communication reflects the authors’ views and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.